An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis
In the U.S., pneumococcal polysaccharide vaccine (PPSV23) uptake among high-risk adults aged <65 years is consistently low and improvement is needed. One barrier to improved vaccine coverage is the complexity of the adult vaccination schedule. This exploratory analysis compared the cost-effective...
Saved in:
Main Authors: | Angela R. Wateska (Author), Mary Patricia Nowalk (Author), Chyongchiou J. Lin (Author), Lee H. Harrison (Author), William Schaffner (Author), Richard K. Zimmerman (Author), Kenneth J. Smith (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old
by: Kenneth J. Smith, et al.
Published: (2017) -
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020) -
Relationships between diets and the quality of life to women aged 50 to 64
by: Ewa Stępień, et al.
Published: (2019) -
Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age
by: Raul E. Isturiz, et al.
Published: (2018) -
Systemic Steroid Treatment for Severe Expanding Pneumococcal Pneumonia
by: Eran Lavi, et al.
Published: (2015)